Micheál Carrigy has met with Biogen which manufactures the drug for Friedreich's Ataxia.
There's a call on the provider of a drug for Friedreich's ataxia to consider a compassionate access scheme.
Negotiations are currently underway between the HSE and Biogen regarding the cost of supplying Skyclarys.
However, the HSE has upheld a recommendation not to reimburse the drug, as it would cost around 280 thousand euro per patient per year.
Fine Gael's Micheál Carrigy met with Biogen, and is recommending an alternative step:
Midlands Gardaí Appeal For Witnesses To Fatal Crash
Midlands Security & Defence Analyst Says Hoax Bomb Threats Aimed To Intimidate
Almost €446,000 Allocated To Midlands Community Centres And Clubhouses
Midlands Family Takes On Ireland’s Fittest Family Challenge
5K Fundraiser To Support Motor Neurone Disease Association Takes Place In Westmeath
No Slowing Down With Age As Westmeath Bowlers Shine At 14th Annual National Bowls Competition
Woman Appears In Court Over €280k Cannabis Seizure In Midlands